Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma

PURPOSE: Multiple myeloma (MM) remains an incurable disease as tumor cells ultimately resist to all available drugs. Homing of tumor cells to the bone marrow microenvironment, involving especially the CXCR4/SDF-1 axis, allows them to survive, proliferate and resist to therapy. F50067, a humanized an...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Fouquet, Guillemette, Guidez, Stéphanie, Richez, Valentine, Stoppa, Anne-Marie, Le Tourneau, Christophe, Macro, Margaret, Gruchet, Cécile, Bobin, Arthur, Moya, Niels, Syshenko, Thomas, Sabirou, Florence, Levy, Anthony, Franques, Paul, Gardeney, Hélène, Karlin, Lionel, Benboubker, Lotfi, Ouali, Monia, Vedovato, Jean-Claude, Ferre, Pierre, Pavlyuk, Mariya, Attal, Michel, Facon, Thierry, Leleu, Xavier
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963612/
https://ncbi.nlm.nih.gov/pubmed/29844860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25156
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia